Dr. Paul Grena, DO

Medicare patients and services

Medicare patients, 2024

949

Services billed

5,643

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 16 companies reported 82 payments worth $6,071 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $407,467 in research payments for these studies, mostly to the institutions running them.

• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
  Eli Lilly and Company · Active, not recruiting · NCT06292013
• A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
  Janssen Research & Development, LLC
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
  Eli Lilly and Company · Active, not recruiting · NCT05556512
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
  Eli Lilly and Company · Completed · NCT04255433
• A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
  Novartis Pharmaceuticals Corporation
• EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
  Boehringer Ingelheim Pharma GmbH & Co.kg
• A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
  Novartis Pharmaceuticals Corporation
• A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
  Janssen Research & Development, LLC
• EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and em…
  Boehringer Ingelheim International GmbH
• A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
  Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Cardiology clinicians in Yardley

• Paul S. Corotto, M.D.
• Brian G. Firth, MD, PHD
• Kevin Furey, DO
• Steven Goldberg, MD
• Bindukumar C. Kansupada, M.D
• Richard T. Leshner, D.O.
• Samuel Stever, DO
• Clifford Strauss, DO